ZSN-76403 | CAS#790676-40-3 | CYP2C19 inhibitor

MedKoo Cat#: 464940 | Name: ZSN-76403

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ZSN-76403 is an inhibitor of the cytochrome P450 (CYP) isoform CYP2C19 (Ki = 0.25 µM). It is selective for CYP2C19 over CYP1A2, -2A6, -2C8, -2C9, -2D6, -2E1, and -3A4 at 1 µM and over CYP2B6 (IC50 = 58 µM). This product has no formal name. For the convenience of scientific communication, we named it by combining its InChi Key (3 letters from the first letter of each section) with the last 5 digit of its CAS#) according to MedKoo Chemical Nomenclature (https://www.medkoo.com/page/naming).

Chemical Structure

ZSN-76403

CAS#790676-40-3

Theoretical Analysis

MedKoo Cat#: 464940

Name: ZSN-76403

CAS#: 790676-40-3

Chemical Formula: C18H18N2O2

Exact Mass: 294.1368

Molecular Weight: 294.35

Elemental Analysis: C, 73.45; H, 6.16; N, 9.52; O, 10.87

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 240.00	2 Weeks
5mg	USD 480.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

ZSN-76403; ZSN 76403; ZSN76403; (+)-N-3-Benzylnirvanol; (S)-N-3-benzyl Nirvanol;

IUPAC/Chemical Name

(S)-3-benzyl-5-ethyl-5-phenylimidazolidine-2,4-dione

InChi Key

ZMZDHUHMXXALFX-SFHVURJKSA-N

InChi Code

InChI=1S/C18H18N2O2/c1-2-18(15-11-7-4-8-12-15)16(21)20(17(22)19-18)13-14-9-5-3-6-10-14/h3-12H,2,13H2,1H3,(H,19,22)/t18-/m0/s1

SMILES Code

O=C([C@@](CC)(NC1=O)C2=CC=CC=C2)N1CC3=CC=CC=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 294.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Cuypers ML, Chanteux H, Gillent E, Bonnaillie P, Saunders K, Beckers C, Delatour C, Dell'Aiera S, Ungell AL, Nicolaï J. (-)-N-3-Benzylphenobarbital Is Superior to Omeprazole and (+)-N-3-Benzylnirvanol as a CYP2C19 Inhibitor in Suspended Human Hepatocytes. Drug Metab Dispos. 2020 Nov;48(11):1121-1128. doi: 10.1124/dmd.120.000089. Epub 2020 Aug 24. PMID: 32839278. 2: Murray JL, Mercer SL, Jackson KD. Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine. Xenobiotica. 2020 Feb;50(2):209-222. doi: 10.1080/00498254.2019.1599465. Epub 2019 Apr 24. PMID: 30902024; PMCID: PMC7755165. 3: Valicherla GR, Mishra A, Lenkalapelly S, Jillela B, Francis FM, Rajagopalan L, Srivastava P. Investigation of the inhibition of eight major human cytochrome P450 isozymes by a probe substrate cocktail in vitro with emphasis on CYP2E1. Xenobiotica. 2019 Dec;49(12):1396-1402. doi: 10.1080/00498254.2019.1581301. Epub 2019 Jun 19. PMID: 30747554. 4: Zakhariants AA, Burmistrova OA, Shkurnikov MY, Poloznikov AA, Sakharov DA. Development of a Specific Substrate-Inhibitor Panel (Liver-on-a-Chip) for Evaluation of Cytochrome P450 Activity. Bull Exp Biol Med. 2016 Nov;162(1):170-174. doi: 10.1007/s10517-016-3567-z. Epub 2016 Nov 23. PMID: 27882460. 5: Zhang J, Li L, Tang S, Hale TW, Xing C, Jiang C, Lü J. Cytochrome P450 Isoforms in the Metabolism of Decursin and Decursinol Angelate from Korean Angelica. Am J Chin Med. 2015;43(6):1211-30. doi: 10.1142/S0192415X1550069X. Epub 2015 Sep 22. PMID: 26394652; PMCID: PMC4872390. 6: Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010 Jan;38(1):92-9. doi: 10.1124/dmd.109.029132. PMID: 19812348. 7: Chang SY, Li W, Traeger SC, Wang B, Cui D, Zhang H, Wen B, Rodrigues AD. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro. Drug Metab Dispos. 2008 Dec;36(12):2513-22. doi: 10.1124/dmd.108.022970. Epub 2008 Sep 11. PMID: 18787056. 8: Driscoll JP, Kornecki K, Wolkowski JP, Chupak L, Kalgutkar AS, O'Donnell JP. Bioactivation of phencyclidine in rat and human liver microsomes and recombinant P450 2B enzymes: evidence for the formation of a novel quinone methide intermediate. Chem Res Toxicol. 2007 Oct;20(10):1488-97. doi: 10.1021/tx700145k. Epub 2007 Sep 25. PMID: 17892269. 9: Emoto C, Iwasaki K. Relative roles of CYP2C19 and CYP3A4/5 in midazolam 1'-hydroxylation. Xenobiotica. 2007 Jun;37(6):592-603. doi: 10.1080/00498250701358749. PMID: 17614006. 10: Sudsakorn S, Skell J, Williams DA, O'Shea TJ, Liu H. Evaluation of 3-O-methylfluorescein as a selective fluorometric substrate for CYP2C19 in human liver microsomes. Drug Metab Dispos. 2007 Jun;35(6):841-7. doi: 10.1124/dmd.106.014472. Epub 2007 Mar 1. PMID: 17332142. 11: Ohhira S, Enomoto M, Matsui H. In vitro metabolism of tributyltin and triphenyltin by human cytochrome P-450 isoforms. Toxicology. 2006 Dec 7;228(2-3):171-7. doi: 10.1016/j.tox.2006.08.023. Epub 2006 Aug 24. PMID: 16978758. 12: Naritomi Y, Terashita S, Kagayama A. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. Xenobiotica. 2004 May;34(5):415-27. doi: 10.1080/00498250410001685728. Erratum in: Xenobiotica. 2004 Jul;34(7):705. PMID: 15370958. 13: Suzuki H, Kneller MB, Rock DA, Jones JP, Trager WF, Rettie AE. Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors. Arch Biochem Biophys. 2004 Sep 1;429(1):1-15. doi: 10.1016/j.abb.2004.05.015. PMID: 15288804. 14: Walsky RL, Obach RS. Verification of the selectivity of (+)N-3-benzylnirvanol as a CYP2C19 inhibitor. Drug Metab Dispos. 2003 Mar;31(3):343. doi: 10.1124/dmd.31.3.343. PMID: 12625332. 15: Suzuki H, Kneller MB, Haining RL, Trager WF, Rettie AE. (+)-N-3-Benzyl- nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. Drug Metab Dispos. 2002 Mar;30(3):235-9. doi: 10.1124/dmd.30.3.235. PMID: 11854139.